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Rifampin-resistant
Neisseria 
meningitidis
To The Editor: Immediate man-
agement of meningococcal disease
requires antimicrobial drug treatment
of patients with β-lactams and chemo-
prophylaxis of contact persons with
rifampin. High-level resistance to
rifampin (MIC >32 mg/L) in
Neisseria meningitidis is provoked by
mutations (most frequently at the
residue His 552) in the rpoB gene
encoding the β subunit of RNA poly-
merase (1,2). Resistance may lead to
chemoprophylaxis failure and must be
rapidly detected (3). Concerns have
been raised about the clonal spread of
resistant isolates (1); however,
rifampin-resistant isolates are rarely
reported. We tested 6 N. meningitidis
isolates corresponding to 3 pairs of
linked cases of meningococcal dis-
ease. In each pair, the index case was
due to a rifampin-susceptible isolate
and was followed by the secondary
case due to a resistant isolate in a con-
tact person. Phenotyping and geno-
typing of the isolates showed that
each pair belonged to a different
major serogroup (A, B, and C) and to
a different genetic lineage (ST-7, ST-
32, and ST-2794) (Figure). We next
amplified a fragment in rpoB between
codons 421 and 701 by using oligonu-
cleotide  rpoBF1 (5′gttttcccagtcac-
gacgttgta-CTGTCCGAAGCCCAA-
CAAAACTCTTGG3′) and rpoBR1
(5′ttgtgagcggataacaatttcTTCCAAG-
AATGGAATCAGGGATGCTGC3′).
The 2 oligonucleotides harbor adap-
tors (in lower case) corresponding to
universal forward and reverse
oligonucleotides that can be used for
sequencing after amplification. We
also analyzed 2 cerebrospinal fluid
(CSF) samples corresponding to 2
linked culture-negative cases of
meningococcal disease in which the
second case was believed to have
been caused by rifampin-resistant
N. meningitidis. These 2 cases were
diagnosed by polymerase chain reac-
tion (PCR) detection of meningococ-
cal DNA, as previously described (4).
The 3 rifampin-susceptible isolates
harbored a wild-type rpoB sequence
(His 552), as did the first CSF sample.
All 3 rifampin-resistant isolates har-
bored a His→Tyr mutation, while
analysis of the second CSF sample
showed a His→Asn mutation
(Figure). Both mutations have been
observed in N. meningitidis (3). No
other difference in the sequence was
seen among all isolates on the ampli-
fied fragment. This approach can rap-
idly detect rpoB mutations and can be
applied to culture-negative clinical
samples.
The virulence of the isolates was
evaluated through their ability to pro-
voke bacteremia in mice after 6-
week-old female BALB/c mice
(Janvier, France) were injected
intraperitoneally. Bacteremia is a
good indicator of bacterial virulence
as it reflects bacterial survival upon
invasion of the bloodstream. The
experimental design was approved by
the Institut Pasteur Review Board.
The rifampin-resistant clinical isolate
LNP22330 showed substantially
reduced bacteremia when compared
to the corresponding susceptible iso-
late LNP21362 (Figure). Such a
reduction was not significant for the
other 2 pairs (LNP18278/LNP18378
and LNP18368/LNP18491), but these
strains were all less virulent than
LNP21362, with ≈1 log10 lower blood
bacterial loads. The 3 pairs of isolates
belonged to different genetic lineages
according to the multilocus sequence
typing typing. Indeed, we have
recently proved that virulence of
meningococcal isolates in the mouse
model depends on the genetic lineage
of the tested isolate (5).
To better study the impact of rpoB
mutation on meningococcal virulence
we constructed an isogenic mutant
strain, NM05-08, by transforming the
susceptible isolate LNP21362 with a
PCR-amplified fragment from a
resistant isolate (LNP22330), as pre-
viously described (6). The PCR frag-
ment corresponded to the product of
amplification between the oligonu-
cleotides ropB1UP (5′ggccgtctgaa-
CTGTCCGAAGCCCAACAAAAC-
TCTTGG3′) and rpoBR1. The oligo-
nucleotide RpoB1UP is the same as
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Figure. Blood bacterial counts in 6-week-old female BALB/c mice (Janvier, France), chal-
lenged intraperitoneally with standardized inocula of 107 colony forming units (CFU) of
rifampin-susceptible (RifS) isolates and their corresponding rifampin-resistant (RifR) iso-
lates. Bacteremia was followed at 2 and 4 h after challenge. Only results after 4 h of chal-
lenge are shown. The name of the isolates tested, their phenotype (susceptibility to
rifampin, RifS or RifR, residue at the position 552 and serogroups B, C, and A), and their
genotype (sequence type ST) are indicated. Results are the means ± standard error (bars)
from groups of at least 5 mice (the number of mice, n, is given above each histogram). p
values were determined by 2-tailed Student t test.LETTERS
the upstream rpoBF1 but with a DNA
uptake sequence (in lower case) that
was added at the 5′ end to permit
DNA transformation (7). The trans-
formant strain NM05-08 was resistant
to rifampin (MIC >32 mg/L), and the
sequence of the rpoB gene confirmed
the His→Tyr mutation. When com-
pared to the parental isolate
(LNP21362), strain NM05-08 showed
reduced virulence. Indeed, bacterial
loads were similar to those observed
for the resistant isolate LNP22330
(Figure). These results strongly sug-
gest a direct negative impact of rpoB
mutations on meningococcal viru-
lence. Mutations in the rpoB gene
have been reported to confer
pleiotropic phenotypes (8). 
The data reported here show that
rifampin-resistant isolates were not
clonal but belonged to different genet-
ic lineages. The results of virulence
assays in mice suggest that mutations
in rpoB in resistant isolates may have
a major biological cost for N. menin-
gitidis, which can be defined as lower
bacterial fitness in terms of survival in
the bloodstream. This biological cost
could explain the lack of clonal
expansion of meningococcal isolates
that acquired resistance to rifampin.
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Vaccination-related
Mycobacterium
bovis BCG Infection 
To the Editor: The high preva-
lence of tuberculosis (TB) underlines
the important role of BCG (bacillus
Calmette-Guérin) immunization. The
vaccine, however, is not free from
complications, which could be local
or disseminated. Disseminated BCG
infection as a result of TB vaccination
is a rare complication with an inci-
dence of 0.06 to 1.56 cases per million
vaccinations; it occurs exclusively in
patients with immune deficits.
However, in these cases, the progno-
sis is unfavorable; up to 70% of
patients die, despite intensive antitu-
berculous treatment (1–4).
A 4-month-old-girl exhibited
enlargement of left axillary lymph
nodes during a 1.5-month period. She
was the second child of healthy par-
ents, with no family history of genetic
disorders or TB. She was vaccinated
according to the regimen compulsory
in Poland: the first dose of BCG and
anti–hepatitis B virus (HBV) vaccina-
tion on the first day of life, followed
by vaccination against diphtheria,
tetanus, pertussis, poliomyelitis, and
the second dose of anti-HBV after 6
weeks. BCG vaccination was per-
formed intradermally in the upper part
of left arm by administration of 0.1
mL Brazilian Moreau strain (Biomed,
Lublin, Poland).
On hospital admission, the patient
was in reasonably good condition but
pale, with grossly enlarged, adjacent
left axillary lymph nodes and
hepatosplenomegaly. Laboratory tests
showed anemia, thrombocytopenia,
elevated transaminase activity, a high
C-reactive protein level, and high
level of immunoglobulin M (IgM)
class anti-cytomegalovirus (CMV)
reactive antibodies. 
Based on clinical manifestations
and biochemical and serologic signs,
CMV infection was suspected. The
patient was administered a 14-day
regimen of ganciclovir (10
mg/kg/day); results of liver function
tests and blood count normalized, and
hepatosplenomegaly decreased.
However, the lymph nodes continued
to enlarge, and diagnostic excision
and bone marrow aspiration were per-
formed to exclude a neoplastic
process. A histopathologic image of
the excised lymph nodes showed
caseating granulomas, and tubercu-
lous lymphadenitis was suggested
(Figure).
At that time, a diagnosis of dis-
seminated BCG infection as a compli-
cation of TB vaccination in a pre-
sumed immunocompromised patient
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